Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
Introduction To Survival Analysis01:18

Introduction To Survival Analysis

115
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
115
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

85
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
85
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

55
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
55
Actuarial Approach01:20

Actuarial Approach

39
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
39
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

314
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
314

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elucidating the Multifaceted Influence Pathway of Spin Regulation on Carrier Dynamics and O<sub>2</sub> Transformation in a Chiral LDO Photocatalytic Framework.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

The Health of Nations Fund: Financing global drug development.

PLOS global public health·2026
Same author

Estimating the global inventory of deprioritized clinical-stage drug development programs: Toward a market for shelved assets.

Drug discovery today·2026
Same author

Plasmid-Free, High-Titer De Novo Adenine Production in <i>Escherichia coli</i> via Modular Pathway Engineering and Adaptive Evolution.

ACS synthetic biology·2026
Same author

Systems Metabolic Engineering of <i>Escherichia coli</i> for High-Titer De Novo β-Thymidine Production via Folate Cycle Enhancement and NADPH Regeneration.

Journal of agricultural and food chemistry·2026
Same author

Systems metabolic engineering for hydroxytyrosol production in <i>Escherichia coli</i>.

Applied and environmental microbiology·2026
Same journal

Brief transdiagnostic cognitive behavioral therapy and expressive writing for hazardous drinking and posttraumatic stress symptoms among sexual and gender minority adults: Pilot trial protocol.

Contemporary clinical trials communications·2026
Same journal

Prehabilitation in lung cancer patients undergoing lung resection surgery (Fit4LungNeo): study protocol.

Contemporary clinical trials communications·2026
Same journal

Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.

Contemporary clinical trials communications·2026
Same journal

Implementation science and the clinical trial workforce: A national needs assessment of training and practice.

Contemporary clinical trials communications·2026
Same journal

Understanding recruitment challenges in Swiss oncology trials: Patient voices from focus groups.

Contemporary clinical trials communications·2026
Same journal

Effectiveness of couple-based maternity education on husbands' involvement in maternity continuum of care service utilization in rural communities of Central Ethiopia: Protocol of cluster randomized controlled trial.

Contemporary clinical trials communications·2026
See all related articles

Related Experiment Video

Updated: May 11, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.1K

Predicting clinical trial duration via statistical and machine learning models.

Joonhyuk Cho1,2,3, Qingyang Xu1, Chi Heem Wong1

  • 1MIT Laboratory for Financial Engineering, Cambridge, MA, USA.

Contemporary Clinical Trials Communications
|April 18, 2025
PubMed
Summary
This summary is machine-generated.

Predicting clinical trial duration using machine learning, specifically DeepSurv, offers accurate insights. This approach aids researchers in optimizing trial designs and reducing drug development financial risks.

Keywords:
Clinical trialCox proportional hazards modelFeature importanceMachine learningSurvival analysis

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

6.9K

Related Experiment Videos

Last Updated: May 11, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.1K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.4K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

6.9K

Area of Science:

  • Biostatistics
  • Machine Learning in Healthcare
  • Clinical Trial Management

Background:

  • Clinical trial duration significantly impacts drug development timelines and costs.
  • Accurate prediction of trial duration is crucial for efficient resource allocation and risk management.
  • Existing methods for predicting clinical trial duration have limitations in accuracy and scope.

Purpose of the Study:

  • To develop and validate advanced predictive models for clinical trial duration.
  • To identify key factors influencing clinical trial duration using a comprehensive dataset.
  • To assess the performance of machine learning models, particularly DeepSurv, in predicting trial duration.

Main Methods:

  • Application of survival analysis and machine learning models.
  • Utilized the largest available dataset for clinical trial duration prediction.
  • Employed neural network-based DeepSurv for enhanced predictive accuracy.

Main Results:

  • DeepSurv demonstrated superior accuracy in predicting clinical trial duration compared to other models.
  • Identified critical factors that significantly influence the length of clinical trials.
  • The developed methodology provides reliable predictions for trial timelines.

Conclusions:

  • Machine learning, especially DeepSurv, offers a powerful tool for predicting clinical trial duration.
  • Optimized trial designs through accurate duration prediction can expedite drug testing.
  • Reduced financial risks in drug development can be achieved, potentially increasing investment in the sector.